Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated ...

A number of equities analysts recently weighed in on TSHA shares. Needham & Company LLC restated a “buy” rating and set a $6.00 target price on shares of Taysha Gene Therapies in a report on ...

In this article, we are going to take a look at where Taysha Gene Therapies, Inc. (NASDAQ:TSHA) stands against the other ...

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) have been given a consensus recommendation of “Buy” by the eight ratings firms that are covering the company, Marketbeat reports.

Taysha Gene Therapies (TSHA) announced that, on February 3, 2025, the Compensation Committee of Taysha’s Board of Directors granted three new ...

Taysha Gene Therapies' TSHA-102 tackles Rett syndrome’s root cause with its miniMECP2 transgene and scAAV delivery. So far, this is TSHA’s main value driver, and it appears safe and effective ...

On Feb. 11, just a few years ago in 1842, Texas’ first and only mutiny occurred on the ship San Antonio as it was anchored in ...

Vesting of the stock option is subject to such employee's continued service to Taysha on each vesting date. About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage ...